Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPTIC S O P versus LANTRISUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPTIC S O P versus LANTRISUL.
CHLOROPTIC S.O.P. vs LANTRISUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Lantrisul (sulfadimethoxine) is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking folic acid synthesis and ultimately nucleic acid production in susceptible bacteria.
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
Intravenous: 3 mg/kg every 8 hours for 14 days, then 5 mg/kg every 12 hours for 14 days; oral: 800 mg (10 mg/kg) twice daily after intravenous phase.
None Documented
None Documented
Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections
Terminal elimination half-life is 18 hours (range 16-20 h). This supports once-daily dosing; steady-state achieved after 3-4 days.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Approximately 70% renal excretion as unchanged drug, 15% fecal elimination via biliary secretion, 10% metabolized to inactive glucuronide conjugate eliminated renally, 5% other minor pathways.
Category C
Category C
Antibiotic
Antibiotic